Identification of novel clinical factors associated with hepatic fat accumulation in extreme obesity

Journal of Obesity

Volumn 2014, Issue , 2014, Pages

  Gerhard, Glenn S ^a   Benotti, Peter ^b   Wood, G Craig ^b   Chu, Xin ^b   Argyropoulos, George ^b   Petrick, Anthony ^b   Strodel, William E ^b   Gabrielsen, Jon D ^b   Ibele, Anna ^b   Still, Christopher D ^b   Kingsley, Christopher ^c   Distefano, Johanna ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Geisinger Obesity Research Institute   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE; CHLORIDE; CORTICOSTEROID; ESTROGEN; FERRITIN; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; METFORMIN; TRIACYLGLYCEROL; ZINC; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; IRON; LIPID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; BODY WEIGHT; CHLORIDE BLOOD LEVEL; CORRELATION ANALYSIS; ERYTHROCYTE COUNT; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; INTRAOPERATIVE PERIOD; IRON BINDING CAPACITY; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; RISK FACTOR; SEX DIFFERENCE; SLEEP DISORDERED BREATHING; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST TO HEIGHT RATIO; ZINC BLOOD LEVEL; BLOOD; COMPLICATION; ENZYMOLOGY; LIVER; METABOLISM; MIDDLE AGED; OBESITY, MORBID; PATHOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

BARIATRIC SURGERY; BIOMARKERS; BLOOD GLUCOSE; FATTY LIVER; FEMALE; HUMANS; IRON; LIPIDS; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY, MORBID; SEVERITY OF ILLNESS INDEX; SLEEP APNEA SYNDROMES; TRIGLYCERIDES;

EID: 84920540265     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2014/368210     Document Type: Article

References (36)

1. Y. Wang, Y. Y. Li, Y. Q. Nie, Y. J. Zhou, C. Y. Cao, and L. Xu, "Association between metabolic syndrome and the development of non-alcoholic fatty liver disease," Experimental andTherapeutic Medicine, vol. 6, no. 1, pp. 77-84, 2013.
2. E. Fabbrini, S. Sullivan, and S. Klein, "Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications," Hepatology, vol. 51, pp. 679-689, 2010.
3. A. L. Birkenfeld and G. I. Shulman, "Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes," Hepatology, vol. 59, no. 2, pp. 713-723, 2014.
4. C. P. Day, "Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease," Liver International, vol. 26, no. 9, pp. 1021-1028, 2006.
5. M. Machado, P. Marques-Vidal, and H. Cortez-Pinto, "Hepatic histology in obese patients undergoing bariatric surgery," Journal of Hepatology, vol. 45, no. 4, pp. 600-606, 2006.
6. A. Naik, A. Belic, U. M. Zanger, and D. Rozman, "Molecular interactions between NAFLD and xenobiotic metabolism," Frontiers in Genetics, vol. 4, article 2, 2013.
7. E. Bugianesi, S.Moscatiello,M. F. Ciaravella, and G.Marchesini, "Insulin resistance in nonalcoholic fatty liver disease," Current Pharmaceutical Design, vol. 16, pp. 1941-1951, 2010.
8. G. Vernon, A. Baranova, and Z. M. Younossi, "Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults," Alimentary Pharmacology and Therapeutics, vol. 34, no. 3, pp. 274-285, 2011.
9. N. Bhala, P. Angulo, D. van der Poorten, E. Lee, J. M. Hui, and G. Saracco, "The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study," Hepatology, vol. 54, no. 4, pp. 1208-1216, 2011.
10. M. Charlton, "Evolving aspects of liver transplantation for nonalcoholic steatohepatitis," Current Opinion in Organ Transplantation, vol. 18, no. 3, pp. 251-258, 2013.
11. E. Hashimoto, M. Taniai, and K. Tokushige, "Characteristics and diagnosis of NAFLD/NASH," Journal of Gastroenterology and Hepatology, vol. 28, supplement 4, pp. 64-70, 2013.
12. M. Gabrielli, F.Moisan,M. Vidal et al., "Steatotic livers. Can we use them in OLTX?Outcome data from a prospective baseline liver biopsy study," Annals of Hepatology, vol. 11, no. 6, pp. 891- 898, 2012.
13. A. Sharma, A. Ashworth, M. Behnke, A. Cotterell, M. Posner, and R. A. Fisher, "Donor selection for adult-to-adult living donor liver transplantation: well begun is half done," Transplantation, vol. 95, no. 3, pp. 501-506, 2013.
14. T. Miyake, T. Kumagi, S. Furukawa et al., "Non-alcoholic fatty liver disease: factors associated with its presence and onset," Journal of Gastroenterology and Hepatology, vol. 28, supplement 4, pp. 71-78, 2013.
15. C. D. Still, G. Craig Wood, X. Chu, C. Manney et al., "Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery," Obesity, vol. 22, no. 3, pp. 888-894, 2013.
16. A. P. Association, Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR), 4th edition, 2000.
17. A. Gorden, R. Yang, L. M. Yerges-Armstrong et al., "Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity," Human Heredity, vol. 75, no. 1, pp. 34-43, 2013.
18. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., "Design and validation of a histological scoring systemfor nonalcoholic fatty liver disease," Hepatology, vol. 41, no. 6, pp. 1313-1321, 2005.
19. G. C. Wood, X. Chu, C. Manney et al., "An electronic health record-enabled obesity database,"BMCMedical Informatics and Decision Making, vol. 12, article 45, 2012.
20. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man," Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
21. K. S. Kim, H. J. Oh, D. J. Kim et al., "The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase levels," Endocrine Journal, vol. 60, no. 12, pp. 1295-1301, 2013.
22. N. Kumashiro, D. M. Erion, D. Zhang et al., "Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 39, pp. 16381-16385, 2011.
23. A. P. DeFilippis, M. J. Blaha, S. S. Martin et al., "Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis," Atherosclerosis, vol. 227, no. 2, pp. 429- 436, 2013.
24. E. K. Speliotes, J. M. Massaro, U. Hoffmann, R. S. Vasan, J. B. Meigs, and D. V. Sahani, "Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study," Hepatology, vol. 51, no. 6, pp. 1979- 1987, 2010.
25. H. Chatrath, R. Vuppalanchi, and N. Chalasani, "Dyslipidemia in patients with nonalcoholic fatty liver disease," Seminars in Liver Disease, vol. 32, no. 1, pp. 22-29, 2012.
26. N. Chalasani, Z. Younossi, J. E. Lavine et al., "The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases," Hepatology, vol. 55, no. 6, pp. 2005-2023, 2012.
27. S. Sookoian and C. J. Pirola, "Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a metaanalysis," Obesity Surgery, vol. 23, no. 11, pp. 1815-1825, 2013.
28. A. E.Mirrakhimov and V. Y. Polotsky, "Obstructive sleep apnea and non-alcoholic fatty liver disease: is the liver another target?" Frontiers in Neurology, vol. 3, article 149, 2012.
29. E. Aigner, I.Theurl,M.Theurl et al., "Pathways underlying iron accumulation in human nonalcoholic fatty liver disease," The American Journal of Clinical Nutrition, vol. 87, no. 5, pp. 1374- 1383, 2008.
30. H. Tsuchiya, Y. Ebata, T. Sakabe, S. Hama, K. Kogure, and G. Shiota, "High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice," Metabolism, vol. 62, no. 1, pp. 62-69, 2013.
31. X. Kang, W. Zhong, J. Liu et al., "Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferatoractivated receptor-alpha," Hepatology, vol. 50, no. 4, pp. 1241- 1250, 2009.
32. T. H. Mikhail, W. G. Nicola, K. H. Ibrahim, S. H. Salama, and M. Emam, "Abnormal zinc and copper metabolism in hepatic steatosis," Bollettino Chimico Farmaceutico, vol. 135, no. 10, pp. 591-597, 1996.
33. J.-M. Lavoie and A. Pighon, "NAFLD, estrogens, and physical exercise: the animal model," Journal of Nutrition and Metabolism, vol. 2012,Article ID 914938, 13 pages, 2012.
34. D. E. Amacher, "The mechanistic basis for the induction of hepatic steatosis by xenobiotics," Expert Opinion on Drug Metabolism and Toxicology, vol. 7, no. 8, pp. 949-965, 2011.
35. P. Letteron, A. Sutton, A. Mansouri, B. Fromenty, and D. Pessayre, "Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice," Hepatology, vol. 38, no. 1, pp. 133-140, 2003.
36. M. Karahashi, M. Hoshina, T. Yamazaki et al., "Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats," Journal of Pharmacological Sciences, vol. 123, no. 4, pp. 356-370, 2013.